Twitter | Search | |
John Perentesis
Moving Forward. Chief of Cinci Cancer Programs. Young adult oncology advocate; COG AYA Vice Chair. Adult-congenital heart survivor. Proud dad. Views my own.
922
Tweets
412
Following
524
Followers
Tweets
John Perentesis retweeted
Marianne Heatherly Feb 23
Loved seeing some of the best life saving doctors in Cincinnati at The Dragonfly Gala last night! Thank you and team for supporting TDF and of course, saving the life of many kids like our Tay Pearl!
Reply Retweet Like
John Perentesis retweeted
Sam Wittekind Feb 19
Excited to work with others at alongside to help measure fitness and promote exercise in this vulnerable population. Awesome collaboration ahead.
Reply Retweet Like
John Perentesis retweeted
NYT Health Feb 16
Penicillin, ibuprofen, aspirin, China is the dominant global supplier of the active ingredient in all of these common drugs. Will a shutdown of factories in China lead to drug shortages in the United States?
Reply Retweet Like
John Perentesis Feb 16
Replying to @bdcoleymd
With 25 gms of protein?
Reply Retweet Like
John Perentesis Feb 16
Reply Retweet Like
John Perentesis Feb 1
Readily available technology could prevent all of this, and increase safety & dramatically reduce costs. EHR -> pharmacy escript -> barcode scans -> dispensing. We focus on cost of new drugs but ignore tech for safety, efficiency & patient satisfaction
Reply Retweet Like
John Perentesis retweeted
JAMA Oncology Jan 22
Reply Retweet Like
John Perentesis retweeted
Kathleen Campbell Jan 17
The Quadruple Aim of Medicine - an incredibly important concept from The American Journal of Medicine 2018 131, 979-986DOI: (10.1016/j.amjmed.2018.04.034)
Reply Retweet Like
John Perentesis Jan 10
Reply Retweet Like
John Perentesis retweeted
cdandoy Jan 8
Large population (n=16,875) case-cohort study to evaluate mucosal barrier injury laboratory-confirmed bloodstream infection in stem cell transplant patients. Incidence, Risk Factors, and Outcomes of Patients Who Develop MBI-LCBI After HSCT
Reply Retweet Like
John Perentesis retweeted
Carl June Jan 3
2020 will be the decade of cell therapy and genome engineering
Reply Retweet Like
John Perentesis Dec 27
Important for all cancer patients but especially where second cancers in conventional x-ray scatter field and collateral organ toxicity (long term cardiac failure, lung fibrosis, etc).
Reply Retweet Like
John Perentesis Dec 24
Happy holidays! Attending with terrific nurses and staff for our awesome and patients and families.
Reply Retweet Like
John Perentesis retweeted
Tim Bonfield Dec 17
A great take on how collaborative science spans time and distance to improve outcomes for children with Congrats Dr. Starczynowski! The study :
Reply Retweet Like
John Perentesis Dec 13
Same concept applies during/between chemotherapy courses in cancer treatment.
Reply Retweet Like
John Perentesis Dec 9
Targeted drugs great until clones escape. Key issue for the next decade. Drug development for TKI resistance with IRAK/FLT3 for AML in lab and
Reply Retweet Like
John Perentesis Dec 9
Couple novel presentations from program - Laura Agresta’s Ven+Vyxeos open clinical trial for relapsed AML & Eric O’Brien preclinical profiling Ven+MCL inhibitors for future studies
Reply Retweet Like
John Perentesis Dec 9
CART transforming VHR ALL therapy Key challenge: half of relapses p CD19 CART are CD19 neg. Novel CD19/CD22 bispecific shows rapid production & safety. 86% morphological CR & 81% MRD negative. 3/7 relapses CD19 neg but patients heavily immune pre tx
Reply Retweet Like
John Perentesis Dec 9
Maureen O’Brien presents phase 2 inotuzumab in r/r CD22+ ALL at w 58% CR/CRi after cycle 1 w 65% MRD negative; incr w subsequent cycles. Excellent single agent response w manageable VOD. Now testing in frontline HR
Reply Retweet Like
John Perentesis retweeted
QuickTake by Bloomberg Dec 1
Something strange happened when Microsoft Japan experimented with giving its employees a 4-day work week — productivity went up
Reply Retweet Like